These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

522 related articles for article (PubMed ID: 20137353)

  • 21. [Effects of neoadjuvant chemotherapy on estrogen and progesterone receptors and HER-2 in breast cancer].
    Zhao J; Wu YL; Wang YD; Zhao GR; Wang J
    Di Yi Jun Yi Da Xue Xue Bao; 2004 Dec; 24(12):1437-9. PubMed ID: 15604081
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes in ER, PR and HER2 receptors status after neoadjuvant chemotherapy in breast cancer.
    Yang YF; Liao YY; Li LQ; Xie SR; Xie YF; Peng NF
    Pathol Res Pract; 2013 Dec; 209(12):797-802. PubMed ID: 24183366
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Correlation of expression of Survivin, BCRP and HER-2 genes with therapeutic response of TE regimen neoadjuvant chemotherapy in breast cancer patients].
    Li X; Li Y; Yang SE; Ma Y; Wen SJ; Guo L; Guli KZ; Zhao B; Liu W; Hu X
    Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):916-20. PubMed ID: 22340101
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of neoadjuvant chemotherapy on breast cancer phenotype, ER/PR and HER2 expression - Implications for the practising oncologist.
    Gahlaut R; Bennett A; Fatayer H; Dall BJ; Sharma N; Velikova G; Perren T; Dodwell D; Lansdown M; Shaaban AM
    Eur J Cancer; 2016 Jun; 60():40-8. PubMed ID: 27062316
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Are we Overtreating Hormone Receptor Positive Breast Cancer with Neoadjuvant Chemotherapy? Role of OncotypeDx
    Kantor O; Barrera E; Kopkash K; Pesce C; Barrera E; Winchester DJ; Yao K
    Ann Surg Oncol; 2019 Oct; 26(10):3232-3239. PubMed ID: 31342379
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients.
    Miglietta L; Morabito F; Provinciali N; Canobbio L; Meszaros P; Naso C; Murialdo R; Boitano M; Salvi S; Ferrarini M
    Eur J Surg Oncol; 2013 Oct; 39(10):1046-52. PubMed ID: 23890870
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of a positive-to-negative change in hormone receptor status after neoadjuvant chemotherapy in patients with hormone receptor-positive breast cancer.
    Chen S; Chen CM; Yu KD; Zhou RJ; Shao ZM
    Ann Surg Oncol; 2012 Sep; 19(9):3002-11. PubMed ID: 22437200
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer.
    Yasojima H; Shimomura A; Naoi Y; Kishi K; Baba Y; Shimazu K; Nakayama T; Kim SJ; Tamaki Y; Noguchi S
    Eur J Cancer; 2011 Aug; 47(12):1779-88. PubMed ID: 21741827
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination of shear wave elastography and Ki-67 index as a novel predictive modality for the pathological response to neoadjuvant chemotherapy in patients with invasive breast cancer.
    Ma Y; Zhang S; Zang L; Li J; Li J; Kang Y; Ren W
    Eur J Cancer; 2016 Dec; 69():86-101. PubMed ID: 27821323
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy.
    Straver ME; Rutgers EJ; Rodenhuis S; Linn SC; Loo CE; Wesseling J; Russell NS; Oldenburg HS; Antonini N; Vrancken Peeters MT
    Ann Surg Oncol; 2010 Sep; 17(9):2411-8. PubMed ID: 20373039
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ER, PgR, HER-2, Ki-67, topoisomerase IIα, and nm23-H1 proteins expression as predictors of pathological complete response to neoadjuvant chemotherapy for locally advanced breast cancer.
    Li XR; Liu M; Zhang YJ; Wang JD; Zheng YQ; Li J; Ma B; Song X
    Med Oncol; 2011 Dec; 28 Suppl 1():S48-54. PubMed ID: 20872186
    [TBL] [Abstract][Full Text] [Related]  

  • 32. De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study.
    Guarneri V; Dieci MV; Bisagni G; Frassoldati A; Bianchi GV; De Salvo GL; Orvieto E; Urso L; Pascual T; Paré L; Galván P; Ambroggi M; Giorgi CA; Moretti G; Griguolo G; Vicini R; Prat A; Conte PF
    Ann Oncol; 2019 Jun; 30(6):921-926. PubMed ID: 30778520
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis.
    Nishimura R; Osako T; Okumura Y; Hayashi M; Arima N
    Breast Cancer; 2010 Oct; 17(4):269-75. PubMed ID: 19730975
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patient and tumor characteristics associated with breast cancer recurrence after complete pathological response to neoadjuvant chemotherapy.
    Ju NR; Jeffe DB; Keune J; Aft R
    Breast Cancer Res Treat; 2013 Jan; 137(1):195-201. PubMed ID: 23149464
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inter-observer agreement among pathologists in grading the pathological response to neoadjuvant chemotherapy in breast cancer.
    Yamaguchi T; Mukai H; Akiyama F; Arihiro K; Masuda S; Kurosumi M; Kodama Y; Horii R; Tsuda H
    Breast Cancer; 2018 Jan; 25(1):118-125. PubMed ID: 28856554
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical significance and prognostic value of receptor conversion in hormone receptor positive breast cancers after neoadjuvant chemotherapy.
    Yang L; Zhong X; Pu T; Qiu Y; Ye F; Bu H
    World J Surg Oncol; 2018 Mar; 16(1):51. PubMed ID: 29514654
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
    Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K
    Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of neoadjuvant chemotherapy on hormone receptor status, HER2/neu and prolactin in breast cancer.
    Pedrini JL; Francalacci Savaris R; Casales Schorr M; Cambruzi E; Grudzinski M; Zettler CG
    Tumori; 2011; 97(6):704-10. PubMed ID: 22322835
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
    Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH
    Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunohistochemical Evaluation of Ki-67 and Comparison with Clinicopathologic Factors in Breast Carcinomas.
    Aman NA; Doukoure B; Koffi KD; Koui BS; Traore ZC; Kouyate M; Toure I; Effi AB
    Asian Pac J Cancer Prev; 2019 Jan; 20(1):73-79. PubMed ID: 30678383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.